Morepen Laboratories Limited — Updates, 11-11-2024: Press Release

Morepen Laboratories reported a robust 64% increase in net profit for Q2’FY25, emphasizing strong financial performance and strategic growth. The company aims for Rs. 5000 crore in revenue by 2030, with a focus on high-margin segments like medical devices and consumer health. Key highlights include a 33% rise in EBITDA and a 9% increase in pharmaceutical revenue. Morepen continues to expand its product line and production capacity, while remaining debt-free and leveraging recent fundraising for future growth initiatives.